Antibiotic dosages in Intensive Care Unit: when and how should we ask for and perform tests?;Dosage des antibiotiques en réanimation : quand et comment demander et interpréter les tests ?

Reanimation

Volumn 15, Issue 3, 2006, Pages 187-192

  Potel, G ^a   Caillon, J ^a   Jacqueline, C ^a   Navas, D ^a   Kergueris, M F ^a   Batard, E ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Antibiotics; ICU; Monitoring

Indexed keywords

ACETYLCYSTEINE; AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; DOBUTAMINE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; ISEPAMICIN; LINEZOLID; MIDAZOLAM; NETILMICIN; NICARDIPINE; PHENYTOIN; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; THEOPHYLLINE; VANCOMYCIN;

DRUG MONITORING; FEBRILE NEUTROPENIA; HUMAN; INTENSIVE CARE UNIT; RESUSCITATION; SHORT SURVEY;

EID: 33747314427     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2006.03.011     Document Type: Short Survey

References (34)

1. Garrafo R., and Lavrut T. Signification clinique des corrélations pharmacocinétique-pharmacodynamie des antibiotiques chez les patients de réanimation. Réanimation 14 (2005) 264-275
2. Barza M., Ioannidis J.P., Cappelleri J.C., and Lau J. Single or multiple daily doses of aminoglycosides : a meta-analysis. BMJ 312 (1996) 338-345
3. Wysocki M., Delatour F., Faurisson F., Rauss A., Pean Y., Misset B., et al. Continuous vs intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomised study. Antimicrob. Agents Chemother. 45 (2001) 2460-2467
4. Mohr J.F., Wanger A., and Rex J.H. Pharmacokinetic-pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn. Microbiol. Infect. Dis. 48 (2004) 125-130
5. Zaske D.E., Sawchuk R.J., Gerding D.R., and Strate R.G. Increased dosage requirements of gentamicin in burn patients. J. Trauma 6 (1976) 824-828
6. Belzberg H., Zhu J., Cornwell III E.E., Murray J.A., Sava J., Salim, et al. Imipenem levels are not predictable in the critically ill patient. J. Trauma 56 (2004) 111-117
7. Young R.J., Lipman J., Gin T., Gomersall C.D., Joynt G.M., and Oh T.E. Intermittent bolus dosing of ceftazidime in critically ill patients. J. Antimicrob. Chemother. 40 (1997) 269-273
8. Lipman J., Wallis S.C., and Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob. Agents Chemother. 43 (1999) 2559-2561
9. Lipman J., Gomersall C.D., Gin T., Joynt G.M., and Young R.J. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J. Antimicrob. Chemother. 43 (1999) 309-311
10. Weinbren M.J. Pharmacokinetics of antibiotics in burn patients. J. Antimicrob. Chemother. 44 (1999) 319-327
11. Navas D., Caillon J., Batard E., Le Conte P., Kergueris M.F., Moreau P., et al. Trough serum concentrations of β-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic-pharmacodynamic properties of β-lactams. Int. J. Antimicrob. Agents 27 (2006) 102-107
12. Kielstein J.T., Czock D., Schopke T., Hafer C., Bode-Boger S.M., Kuse E., et al. Pharmacokinetics and total elimination nof meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit. Care Med. 34 (2006) 51-56
13. Trotman R.L., Williamson J.C., Shoemaker D.M., and Salzer W.M. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41 (2005) 1159-1166
14. Fish D.N., Teitelbaum I., and Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother. 49 (2005) 2421-2428
15. DelDot M.E., Lipman J., and Tett S.E. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br. J. Clin. Pharmacol. 58 (2004) 259-268
16. Capparelli E., Hochwald C., Rasmussen M., Parham A., Bradley J., and Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob. Agents Chemother. 49 (2005) 2760-2766
17. Moore R.D., Lietman P.S., and Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155 (1987) 93-99
18. Rybak M.J., Abate B.J., Kang S.L., Ruffing M.J., Lerner S.A., and Drusano G.L. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43 (1999) 1549-1555
19. Hansen M., Christrup L.L., Jarlov J.O., Kampmann J.P., and Bonde J. Gentamicin dosing in critically ill patients. Acta Anesthesiol. Scand. 45 (2001) 734-740
20. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornseif B., et al. Pharmacodynamics of levofloxacin: a new paradigm for new clinical trials. JAMA 279 (1998) 125-129
21. Robaux M.A., Dube L., Caillon J., Bugnon D., Kergueris M.F., Navas D., et al. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. Antimicrob. Chemother. 47 (2001) 617-622
22. Manduru M., Mihm L.B., White R.L., Friedrich L.W., Flume R.A., and Bosso J.A. In vitro pharmacodynamics of ceftazidime against P. aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 41 (1997) 2053-2056
23. Navas D., Caillon J., Gras-LeGuen C., Jacqueline C., Kergueris M.F., Bugnon D., et al. Comparison of in vivo intrinsic activity of cefepime and imipenem in a P. aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. J. Antimicrob. Chemother. 54 (2004) 767-771
24. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., and Falagas M.E. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect. Dis. 5 (2005) 581-589
25. Georges B., Conil J.M., Cougot P., Decun J.F., Archambaud M., Seguin T., et al. Cefepime in critically ill patients: continuous infusion vs an intermittent dosing regimen. Int. J. Clin. Pharmacol. Ther. 43 (2005) 360-369
26. Frei C.R., and Burgess D.S. Continuous infusion beta-lactams for intensive care unit pulmonary infections. Clin. Microbiol. Infect. 11 (2005) 418-421
27. Tam V.H., Louie A., Lomaestro B.M., and Drusano G.L. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against P. aeruginosa. Pharmacotherapy 23 (2003) 291-295
28. Boselli E., Breilh D., Duflo F., Saux M.C., Debon R., Chassard D., et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit. Care Med. 8 (2003) 2102-2106
29. Boselli E., Breilh D., Rimmele T., Poupelin J.C., Saux M.C., Chassard D., et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 30 (2004) 989-991
30. Baririan N., Chanteux H., Viaene E., Servais H., and Tulkens P.M. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J. Antimicrob. Chemother. 51 (2003) 651-658
31. Boselli E., Breilh D., Rimmele T., Djabarouti S., Toutain J., Chassard D., et al. Pharmacokinetics and intrapulmonary concentraitons of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit. Care Med. 33 (2006) 1654-1655
32. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17 (2003) 479-501
33. Jacqueline C., Batard E., Perez L., Boutoille D., Hamel A., Caillon J., et al. In vivo efficacy of continuous infusion vs intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant S. aureus rabbit endocarditis model. Antimicrob. Agents Chemother. 46 (2002) 2706-2711
34. Darko W., Medicis J.J., Smith A., Guharoy R., and Lehmann D.E. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustement of vancomycin to prevent nephrotoxicity. Pharmacotherapy 23 (2003) 643-650